Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07619729
Enrolling by invitation Phase 4

Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With Diabetes

NCT07619729 · tracked via the Priya Life Science USA tracker
Sponsor
Colgate Palmolive
Phase
Phase 4
Started
2026-05-26
Last updated
2026-09-03

Condition(s) studied

Diabetes Type 2Periodontal DiseaseCaries

Investigational drug(s) / intervention(s)

Diabetes Oral Health ProgramStannous Fluoride Dentifrice →Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash

Diabetes Oral Health Program: All subjects will receive a behavioral intervention through text messages with links to educational pages about oral health or diabetes. Subjects will have the option of selecting in to the product intervention.

Stannous Fluoride Dentifrice: This is an opt-in product intervention, and it is expected that not all subjects will opt-in. Subjects will need to re-order the product every 3 months. All subjects who order product will receive a toothbrush, toothpaste, and mouthwash.

Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash: This is an opt-in product intervention, and it is expected that not all subjects will opt-in. Subjects will need to re-order the product every 3 months. All subjects who order product will receive a toothbrush, toothpaste, and mouthwash.

Study summary

The purpose of this clinical study is to evaluate the effect of a behavioral intervention on the number of preventive and treatment dental claims in a population of people with Type 2 Diabetes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Consented to participation in the Fidelis Care Diabetes Care program. * Aged 18 years and older * English speaking. * Willing and able to receive text messages, and participate in online activities for the duration of the program. * Diagnosis of Type 2 Diabetes. Exclusion Criteria: * Severe cognitive impairment. * General anesthesia in the past 3 months. * Type 1 diabetes. * Self-reported pregnant.

Primary outcome measure(s)

  • Dental Claims — 12 months
    Percentage of preventive dental claims compared to treatment dental claims

Trial sites (1)

FacilityCityRegionStatus
Decentralized Site - Virtual/Remote (NY, USA) Long Island City New York

More Colgate Palmolive trials in the USA

Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis Recruiting
Investigation of the Interplay Between Local Oral Inflammation, Microbiota and Systemic Immune Responses. Starting soon
Enamel Lesion Detection With New DX Tool Starting soon
To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. Active, not recruiting

Other trials for the same condition

Enamel Lesion Detection With New DX Tool Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07619729 on ClinicalTrials.gov ↗ ← All trials in the USA